Feasibility of MR-guided needle-directed intratumoral HoMS delivery for localized radiation therapy in a large tumor model

Bo Sybren van Leeuwen, Sebastiaan Alexander van Nimwegen, Frank Zijlstra, Chris Oerlemans, Jolle Kirpensteijn, Johannes Franciscus Nijssen, and Peter Roland Seevinck

1 Dept. of Clinical Sciences of Companion Animals, Faculty of Veterinary Medicine Utrecht University, Utrecht, Utrecht, Netherlands, 2 Dept. of Clinical Sciences of Companion Animals, Faculty of Veterinary Medicine Utrecht University, Utrecht, Netherlands, 3 Image Sciences Institute, Imaging Division, University Medical Center Utrecht, Utrecht, Utrecht, Netherlands

Introduction
Radioablation by direct intratumoral administration of paramagnetic and radioactive holmium microspheres (166HoMS; 10-20µm diameter) is a promising treatment option for solid, unresectable tumors, especially in areas where the preservation of surrounding tissue and function is essential (e.g., brain, head and neck region). Intratumoral efficacy of 166HoMS was previously demonstrated for the treatment of small (4-8 mm) implanted renal carcinoma tumors in mice with a single intratumoral injection [1]. However, in larger tumors the penetration range of the beta particles necessitates a certain volume distribution of radioactive 166HoMS in the tissue in order to be effective. Therefore multiple well-directed injections may be needed to obtain a more favourable distribution of 166HoMS inside the tissue [1]. Consequently, precise needle placement and verification of 166HoMS distribution after intratumoral injection is required. Interestingly, it was recently demonstrated that MRI can be utilized for T2*-based quantitative assessment of the spatial distribution and dosimetry of 166HoMS, besides identification of the tumorous and healthy tissue [2]. The goal of the present study is to demonstrate the feasibility of MR-guided needle-directed intratumoral delivery of 166HoMS in a large tumor model.

Material and Methods

Experimental setup and animal preparation: 166HoMS were prepared by solvent evaporation, resulting in a size distribution of 10-20 µm and a holmium content of 17 % by weight, as described previously [7]. Vx2 tumors in the hind limb of New Zealand White rabbits was achieved by subcutaneous injection of viable tumor pieces and the rabbits treated after the tumor reached a size around 2-4 cm. Prior to scanning, a cylindrical container was placed over the hind limb and filled with agarose, to enable needle MR image-based entry point optimization. Treatment planning: The desired injection site within the tumor was determined pre-treatment on an anatomical T2 weighted TSE scan (Fig. 1a). The needle entry point and preferred trajectory was determined on a 3D gradient echo images, reformatted to the desired orientation (Fig. 1b, c). Needle positioning and 166HoMS administration: 166HoMS injections were performed using titanium needles (MRI chiba, Somatex, 22G, 0.7mm, 100mm) under MRI-guidance (1.5T whole body MR scanner Achieva; Philips Healthcare, Best, The Netherlands). Needle positioning was facilitated by dynamic 2D dual-plane free induction decay (FID) sampling, which allowed for coRASOR reconstructions to highlight the needles with positive contrast [4] (Fig. 2II).

Dynamic visualization of 166HoMS delivery was facilitated using the same 2D sequences (Fig. 2DI and II). After 166HoMS administration, spatial distribution was investigated using 3D multi-echo gradient echo sequences, as the presence of paramagnetic HoMS induces signal voids due to dephasing (Fig. 2Ilia, b). Needle visualization: Needle visualization with positive contrast was facilitated by co-RASOR reconstruction applied to a 2D radial center-out sampling sequence [4]. By introducing a frequency offset, Δf (-2000Hz), to the central reception frequency, f0, during reconstruction [5], the titanium needle could be visualised at its exact location with high positive contrast [4,5]. Imaging parameters included: TR/TE = 3.5/ 0.8 ms; scan matrix = 128 x 128, FOV = 192x192 mm²; slice thickness = 6 or 8 mm, flip = 25, dynamic scan time = 0.9s.

Results
The tumor and surrounding tissue were clearly visualised on the T2w TSE (Fig 1a) and on the reformatted 3D gradient echo images (Fig. 1b, c) prior to 166HoMS delivery. Based on these images, an entry point, preferred needle trajectory and slice location was defined, resulting in the slice shown in Fig. 2c. Needle insertion was performed, successfully monitored using the dynamic 2D dual plane sequence. Fig2a-d presents the conventional (row I) and coRASOR reconstructed (row II) images, clearly demonstrating that coRASOR facilitates high contrast visualization of the needle. Successful HoMS delivery into the tumor was shown in Fig. 2d, which was confirmed post injection in the 3D gradient echo data, showing signal voids in the center of the tumor (Fig. 2IIia, b). Finally, Fig. 3 demonstrates the added value of consecutive HoMS injections, clearly showing an improved tumor coverage after the second injection as compared to a single injection. Although, five out of six injections were successful, one injection resulted in peri-tumoral delivery of HoMS.

Discussion & conclusion
In this study, we demonstrated the feasibility of MR-guided needle-directed intratumoral 166HoMS delivery in a large tumor model. MRI facilitated tumor visualization, entry point determination and needle trajectory planning. The presented approach enabled dynamic monitoring of the needle insertion and needle tip positioning in the tumor, allowing intraprocedural optimization of HoMS delivery. In five out of six attempts, HoMS was successfully delivered in the tumor. As coRASOR reconstruction was demonstrated retrospectively to improve needle visualization by generating positive contrast, causing the titanium needles to be easily identified with high spatial and temporal resolution, its prospective implementation currently has high priority. Future work should also aim at facilitating intraprocedural dosimetry to enable optimization of the number of injection sites and the amount of HoMS to be delivered to eventually provide a favorable dose distribution on the tumor, while sparing the healthy tissue.

References